Tectonic Therapeutic (TECX) Non-Current Deffered Revenue (2017 - 2022)
Tectonic Therapeutic (TECX) posted quarterly Non-Current Deffered Revenue of $10000.0 for Q3 2022, down 88.89% year-over-year from $90000.0 in Q3 2021, and down 16.67% quarter-over-quarter from $12000.0 in Q2 2022.
Powered by 
Analysis
Tectonic Therapeutic (TECX) Non-Current Deffered Revenue (2017 - 2022) Analysis & Trends
Tectonic Therapeutic (TECX) has reported Non-Current Deffered Revenue for 6 consecutive years, with $10000.0 the latest figure, recorded in Q3 2022.
- In Q3 2022, Non-Current Deffered Revenue fell 88.89% year-over-year to $10000.0; the TTM figure through Sep 2022 stood at $10000.0 (down 88.89% YoY), while the FY2021 annual figure was $30000.0, down 89.13% from the prior year.
- Non-Current Deffered Revenue fell to $10000.0 in Q3 2022 per TECX's latest filing, from $12000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $781000.0 in Q2 2018 and bottomed at $10000.0 in Q3 2022.
- Historically, Non-Current Deffered Revenue has averaged $340722.2 across 5 years, with a median of $303500.0 in 2020.
- Annual changes were most pronounced in 2018 — Non-Current Deffered Revenue surged 446.83% — and 2022, when it slumped 92.0%.
- Tectonic Therapeutic's Non-Current Deffered Revenue stood at $689000.0 in 2018, then tumbled by 68.94% to $214000.0 in 2019, then gained by 28.97% to $276000.0 in 2020, then slumped by 89.13% to $30000.0 in 2021, then slumped by 66.67% to $10000.0 in 2022.
- Business Quant data shows TECX's Non-Current Deffered Revenue at $10000.0 in Q3 2022, $12000.0 in Q2 2022, and $30000.0 in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Tectonic Therapeutic | 589.02 Mn | 589.02 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 10,000.00 |
| Jun 30, 2022 | 12,000.00 |
| Mar 31, 2022 | 30,000.00 |
| Dec 31, 2021 | 30,000.00 |
| Sep 30, 2021 | 90,000.00 |
| Jun 30, 2021 | 150,000.00 |
| Mar 31, 2021 | 214,000.00 |
| Dec 31, 2020 | 276,000.00 |
| Sep 30, 2020 | 331,000.00 |
| Jun 30, 2020 | 370,000.00 |
| Mar 31, 2020 | 430,000.00 |
| Dec 31, 2019 | 484,000.00 |
| Sep 30, 2019 | 535,000.00 |
| Jun 30, 2019 | 590,000.00 |
| Mar 31, 2019 | 645,000.00 |
| Dec 31, 2018 | 689,000.00 |
| Sep 30, 2018 | 736,000.00 |
| Jun 30, 2018 | 781,000.00 |
| Dec 31, 2017 | 126,000.00 |